Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.
Identifieur interne : 001E09 ( PubMed/Curation ); précédent : 001E08; suivant : 001E10Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.
Auteurs : Yasuko Tsunetsugu-Yokota [Japon] ; Manabu Ato ; Yoshimasa Takahashi ; Shu-Ichi Hashimoto ; Tomohiro Kaji ; Masayuki Kuraoka ; Ki-Ichi Yamamoto ; Yu-Ya Mitsuki ; Takuya Yamamoto ; Masamichi Oshima ; Kazuo Ohnishi ; Toshitada TakemoriSource :
- Japanese journal of infectious diseases [ 1344-6304 ] ; 2007.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (sang), Femelle, Formaldéhyde (pharmacologie), Humains, Lymphocytes auxiliaires Th2 (immunologie), Rayons ultraviolets, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (effets indésirables), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins inactivés.
- effets indésirables : Vaccins antiviraux, Vaccins inactivés.
- immunologie : Lymphocytes auxiliaires Th2, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- pharmacologie : Formaldéhyde.
- sang : Anticorps antiviraux.
- Animaux, Femelle, Humains, Rayons ultraviolets, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Female, Formaldehyde (pharmacology), Humans, Mice, Mice, Inbred BALB C, SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Th2 Cells (immunology), Ultraviolet Rays, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (adverse effects), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, Inactivated, Viral Vaccines.
- chemical , adverse effects : Vaccines, Inactivated, Viral Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Vaccines, Inactivated, Viral Vaccines.
- chemical , pharmacology : Formaldehyde.
- immunology : SARS Virus, Th2 Cells.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Female, Humans, Mice, Mice, Inbred BALB C, Ultraviolet Rays.
Abstract
The demand for rapid and simple development of a vaccine against a newly emerging infectious disease is increasing worldwide. We previously revealed that UV-inactivated severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) virions (UV-V) elicited high levels of humoral immunity and a weak Th0 response in mice immunized subcutaneously. To ensure the safety of such a whole inactivated SARS-CoV vaccine, we additionally treated the UV-V vaccine with formalin, resulting in the UV-F-V vaccine. Analysis of the immunogenicity of the UV-F-V+alum vaccine in mice revealed that it generated comparable neutralizing serum anti-SARS-CoV IgG antibody levels as the UV-V+alum vaccine. Moreover, both vaccines induced similar frequencies of anti-SARS-CoV IgG antibody-producing cells in bone marrow. Interestingly, the UV-F-V vaccine induced fewer IgG(2a) subtype antibodies and higher interleukin-4 production in vaccinated mice than did UV-V. Thus, UV-F-V imposes a Th2-type bias on the immune response, unlike UV-V. We propose here that doubly-inactivated SARS-CoV virions by UV and formalin constitute a safe vaccine that may effectively induce neutralizing antibodies in humans.
PubMed: 17515642
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E09
Links to Exploration step
pubmed:17515642Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.</title><author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. yyokota@nih.go.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640</wicri:regionArea></affiliation></author><author><name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name></author><author><name sortKey="Takahashi, Yoshimasa" sort="Takahashi, Yoshimasa" uniqKey="Takahashi Y" first="Yoshimasa" last="Takahashi">Yoshimasa Takahashi</name></author><author><name sortKey="Hashimoto, Shu Ichi" sort="Hashimoto, Shu Ichi" uniqKey="Hashimoto S" first="Shu-Ichi" last="Hashimoto">Shu-Ichi Hashimoto</name></author><author><name sortKey="Kaji, Tomohiro" sort="Kaji, Tomohiro" uniqKey="Kaji T" first="Tomohiro" last="Kaji">Tomohiro Kaji</name></author><author><name sortKey="Kuraoka, Masayuki" sort="Kuraoka, Masayuki" uniqKey="Kuraoka M" first="Masayuki" last="Kuraoka">Masayuki Kuraoka</name></author><author><name sortKey="Yamamoto, Ki Ichi" sort="Yamamoto, Ki Ichi" uniqKey="Yamamoto K" first="Ki-Ichi" last="Yamamoto">Ki-Ichi Yamamoto</name></author><author><name sortKey="Mitsuki, Yu Ya" sort="Mitsuki, Yu Ya" uniqKey="Mitsuki Y" first="Yu-Ya" last="Mitsuki">Yu-Ya Mitsuki</name></author><author><name sortKey="Yamamoto, Takuya" sort="Yamamoto, Takuya" uniqKey="Yamamoto T" first="Takuya" last="Yamamoto">Takuya Yamamoto</name></author><author><name sortKey="Oshima, Masamichi" sort="Oshima, Masamichi" uniqKey="Oshima M" first="Masamichi" last="Oshima">Masamichi Oshima</name></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name></author><author><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17515642</idno><idno type="pmid">17515642</idno><idno type="wicri:Area/PubMed/Corpus">001E09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E09</idno><idno type="wicri:Area/PubMed/Curation">001E09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E09</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.</title><author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. yyokota@nih.go.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640</wicri:regionArea></affiliation></author><author><name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name></author><author><name sortKey="Takahashi, Yoshimasa" sort="Takahashi, Yoshimasa" uniqKey="Takahashi Y" first="Yoshimasa" last="Takahashi">Yoshimasa Takahashi</name></author><author><name sortKey="Hashimoto, Shu Ichi" sort="Hashimoto, Shu Ichi" uniqKey="Hashimoto S" first="Shu-Ichi" last="Hashimoto">Shu-Ichi Hashimoto</name></author><author><name sortKey="Kaji, Tomohiro" sort="Kaji, Tomohiro" uniqKey="Kaji T" first="Tomohiro" last="Kaji">Tomohiro Kaji</name></author><author><name sortKey="Kuraoka, Masayuki" sort="Kuraoka, Masayuki" uniqKey="Kuraoka M" first="Masayuki" last="Kuraoka">Masayuki Kuraoka</name></author><author><name sortKey="Yamamoto, Ki Ichi" sort="Yamamoto, Ki Ichi" uniqKey="Yamamoto K" first="Ki-Ichi" last="Yamamoto">Ki-Ichi Yamamoto</name></author><author><name sortKey="Mitsuki, Yu Ya" sort="Mitsuki, Yu Ya" uniqKey="Mitsuki Y" first="Yu-Ya" last="Mitsuki">Yu-Ya Mitsuki</name></author><author><name sortKey="Yamamoto, Takuya" sort="Yamamoto, Takuya" uniqKey="Yamamoto T" first="Takuya" last="Yamamoto">Takuya Yamamoto</name></author><author><name sortKey="Oshima, Masamichi" sort="Oshima, Masamichi" uniqKey="Oshima M" first="Masamichi" last="Oshima">Masamichi Oshima</name></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name></author><author><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></author></analytic><series><title level="j">Japanese journal of infectious diseases</title><idno type="ISSN">1344-6304</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Female</term><term>Formaldehyde (pharmacology)</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Th2 Cells (immunology)</term><term>Ultraviolet Rays</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (adverse effects)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Femelle</term><term>Formaldéhyde (pharmacologie)</term><term>Humains</term><term>Lymphocytes auxiliaires Th2 (immunologie)</term><term>Rayons ultraviolets</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (effets indésirables)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (effets indésirables)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Formaldehyde</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes auxiliaires Th2</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Th2 Cells</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Formaldéhyde</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Ultraviolet Rays</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Humains</term><term>Rayons ultraviolets</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The demand for rapid and simple development of a vaccine against a newly emerging infectious disease is increasing worldwide. We previously revealed that UV-inactivated severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) virions (UV-V) elicited high levels of humoral immunity and a weak Th0 response in mice immunized subcutaneously. To ensure the safety of such a whole inactivated SARS-CoV vaccine, we additionally treated the UV-V vaccine with formalin, resulting in the UV-F-V vaccine. Analysis of the immunogenicity of the UV-F-V+alum vaccine in mice revealed that it generated comparable neutralizing serum anti-SARS-CoV IgG antibody levels as the UV-V+alum vaccine. Moreover, both vaccines induced similar frequencies of anti-SARS-CoV IgG antibody-producing cells in bone marrow. Interestingly, the UV-F-V vaccine induced fewer IgG(2a) subtype antibodies and higher interleukin-4 production in vaccinated mice than did UV-V. Thus, UV-F-V imposes a Th2-type bias on the immune response, unlike UV-V. We propose here that doubly-inactivated SARS-CoV virions by UV and formalin constitute a safe vaccine that may effectively induce neutralizing antibodies in humans.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17515642</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1344-6304</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>2-3</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Japanese journal of infectious diseases</Title><ISOAbbreviation>Jpn. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.</ArticleTitle><Pagination><MedlinePgn>106-12</MedlinePgn></Pagination><Abstract><AbstractText>The demand for rapid and simple development of a vaccine against a newly emerging infectious disease is increasing worldwide. We previously revealed that UV-inactivated severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) virions (UV-V) elicited high levels of humoral immunity and a weak Th0 response in mice immunized subcutaneously. To ensure the safety of such a whole inactivated SARS-CoV vaccine, we additionally treated the UV-V vaccine with formalin, resulting in the UV-F-V vaccine. Analysis of the immunogenicity of the UV-F-V+alum vaccine in mice revealed that it generated comparable neutralizing serum anti-SARS-CoV IgG antibody levels as the UV-V+alum vaccine. Moreover, both vaccines induced similar frequencies of anti-SARS-CoV IgG antibody-producing cells in bone marrow. Interestingly, the UV-F-V vaccine induced fewer IgG(2a) subtype antibodies and higher interleukin-4 production in vaccinated mice than did UV-V. Thus, UV-F-V imposes a Th2-type bias on the immune response, unlike UV-V. We propose here that doubly-inactivated SARS-CoV virions by UV and formalin constitute a safe vaccine that may effectively induce neutralizing antibodies in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsunetsugu-Yokota</LastName><ForeName>Yasuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. yyokota@nih.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ato</LastName><ForeName>Manabu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Yoshimasa</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Shu-ichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kaji</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kuraoka</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Ki-ichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mitsuki</LastName><ForeName>Yu-ya</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Takuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Oshima</LastName><ForeName>Masamichi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ohnishi</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Takemori</LastName><ForeName>Toshitada</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Jpn J Infect Dis</MedlineTA><NlmUniqueID>100893704</NlmUniqueID><ISSNLinking>1344-6304</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014466" MajorTopicYN="N">Ultraviolet Rays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17515642</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E09 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001E09 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17515642
|texte= Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17515642" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |